Uranium Energy Draws Institutional Bulls as Wall Street Disagrees on Price

Large money managers are piling into Uranium Energy Corp. (UEC) despite the stock sitting roughly 24 percent below its 52-week high. Massachusetts Financial Services Co. bought roughly 1.9 million shares in the fourth quarter, a stake worth around $22 million. Vanguard expanded its position by more than a third over the same period, while Voya Investment Management nearly tripled its holdings. Hedge funds and institutional investors now control over 62 percent of the company’s outstanding shares.

The buying spree reflects a bet on domestic US uranium production at a time when geopolitical risks threaten supply from Russia and Kazakhstan. The United States currently imports about 95 percent of its uranium needs, and rising demand for nuclear power is putting pressure on the country to develop its own sources.

Uranium Energy is now the only US company operating two active in-situ recovery production platforms. The second mine, Burke Hollow in Wyoming, recently started production — the first new ISR facility built in the country in more than a decade. Only half of the Burke Hollow site has been explored so far, and the company calls it the largest American ISR uranium discovery of the past decade.

The company’s total annual production capacity stands at roughly 12 million pounds. Management plans to bring the Ludeman project in Wyoming online by 2027. Beyond mining, Uranium Energy is pursuing a vertical integration strategy. A subsidiary has received a docket number from the US nuclear regulator for a planned uranium conversion facility. Once the planning phase is complete, the company will file a formal license application. If successful, Uranium Energy would become the only US producer with its own uranium and UF6 processing capabilities, a move that could structurally boost profit margins.

Should investors sell immediately? Or is it worth buying Uranium Energy?

UEC sells all of its production on the spot market without hedging. That strategy paid off in the second fiscal quarter, when the company sold 200,000 pounds of uranium at $101 per pound — roughly 25 percent above the prevailing market average at the time. The broader uranium market has been mixed recently. US spot contracts fell to $85 per pound in March, while long-term supply agreements have risen nearly 10 percent since the start of the year.

The stock trades at €12.29 in Europe, down about 27 percent from its January high. Over the past 12 months, shares have still gained roughly 165 percent. The second source puts the gain at nearly 177 percent, reflecting minor currency and timing differences.

Wall Street is split on where the stock goes from here. A net asset value model pegs fair value at $19.11, suggesting significant upside. A discounted cash flow model arrives at just $13.05, implying the stock is already overvalued. Among nine analysts covering the company, seven rate it a buy. The average price target sits at $17.53. Roth MKM maintains a buy rating, while BMO Capital Markets keeps a hold rating, citing elevated valuation.

The debate among analysts centers not on the company’s operational execution but on the premium investors should pay for an unhedged uranium platform exposed to volatile spot prices. The next leg for the stock will depend on whether management can bring Burke Hollow, Ludeman, and the planned conversion facility online without delays while uranium prices hold steady.